109 related articles for article (PubMed ID: 26680567)
1. Comparison of clinical cut-points and treatment targets for urine NTX and plasma βCTX-I in osteoporosis.
Chubb SA; Mandelt C; Vasikaran S
Clin Biochem; 2016 May; 49(7-8):529-33. PubMed ID: 26680567
[TBL] [Abstract][Full Text] [Related]
2. Comparison of results from commercial assays for plasma CTX: The need for harmonization.
Chubb SA; Mandelt CD; Vasikaran SD
Clin Biochem; 2015 May; 48(7-8):519-24. PubMed ID: 25773259
[TBL] [Abstract][Full Text] [Related]
3. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
4. Measurement and Clinical Utility of βCTX in Serum and Plasma.
Chubb SAP; Vasikaran SD
Adv Clin Chem; 2017; 81():97-134. PubMed ID: 28629592
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
Baxter I; Rogers A; Eastell R; Peel N
Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
[TBL] [Abstract][Full Text] [Related]
7. Course of NTX changes under continuous bisphosphonate treatment in cases of NTX over-reduction due to long-term treatment with bisphosphonates.
Iba K; Takada J; Sasaki K; Wada T; Yamashita T
J Orthop Sci; 2011 Jan; 16(1):71-6. PubMed ID: 21290152
[TBL] [Abstract][Full Text] [Related]
8. [Age-related and menopause-related changes of urinary excretion of C- and N-terminal cross-linked telopeptides of type I collagen and the relationships thereof with menopause-related bone loss].
Liu SP; Liao EY; Wu XP; Cao XZ; Shan PF; Su X
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):371-5. PubMed ID: 16677543
[TBL] [Abstract][Full Text] [Related]
9. Urinary NTX results rarely alter the clinical management of patients with osteoporosis in the tertiary hospital.
Gillett MJ; Vasikaran SD
Pathology; 2006 Feb; 38(1):49-52. PubMed ID: 16484009
[TBL] [Abstract][Full Text] [Related]
10. Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Yanada S; Hatano T; Igarashi H; Kishimoto K; Nakada J; Yoshihiro A; Harada J
Metabolism; 2002 Jul; 51(7):814-8. PubMed ID: 12077723
[TBL] [Abstract][Full Text] [Related]
11. Urinary cross-linked N-telopeptides of type I collagen and bone metabolic diseases.
Xue Y; Jia W; Zhang H; Dong J; Clemens JD; Tian X
Chin Med J (Engl); 1999 Feb; 112(2):149-52. PubMed ID: 11593583
[TBL] [Abstract][Full Text] [Related]
12. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
13. [Suggestions for standardized collection of morning urine for assessment of NTx levels in patients with osteoporosis].
Wendlová J
Vnitr Lek; 2001 Jan; 47(1):30-5. PubMed ID: 15635866
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
[TBL] [Abstract][Full Text] [Related]
15. Urinary N-telopeptides of type I collagen in healthy children.
Sato J; Hasegawa K; Tanaka H; Morishima T
Pediatr Int; 2010 Jun; 52(3):398-401. PubMed ID: 20113422
[TBL] [Abstract][Full Text] [Related]
16. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
17. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density.
Schneider DL; Barrett-Connor EL
Arch Intern Med; 1997 Jun; 157(11):1241-5. PubMed ID: 9183236
[TBL] [Abstract][Full Text] [Related]
18. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.
Reid IR; Davidson JS; Wattie D; Wu F; Lucas J; Gamble GD; Rutland MD; Cundy T
Bone; 2004 Jul; 35(1):224-30. PubMed ID: 15207761
[TBL] [Abstract][Full Text] [Related]
19. Urinary cross-linked N-telopeptides of type I collagen levels in patients with rheumatoid arthritis.
Iwamoto J; Takeda T; Ichimura S
Calcif Tissue Int; 2003 Apr; 72(4):491-7. PubMed ID: 12574873
[TBL] [Abstract][Full Text] [Related]
20. [A comparison of the measurements with biochemical markers of bone turnover and bone mineral density in the assessment of the efficiency of osteoporosis treatment].
Ataoğlu MB; Atik OŞ; Gül O; Sarıkaya B; Görmeli G; Öztürk BY; Özgürol B
Eklem Hastalik Cerrahisi; 2013; 24(2):82-6. PubMed ID: 23692194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
